Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma
The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant ve...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | YU YIZHI LI CHUNZHEN YIN SHULEI XUE YIQUAN SHEN XIN TAO YIJIE XU SHENG WU YUNYANG |
| description | The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant vector and a hepatocellular carcinoma treatment pharmaceutical composition taking the SCRN1 inhibitor or a recombinant expression vector thereof as an active component. Experimental results show that the expression of SCRN1 in tumor tissues is increased, normal proliferation of liver cancer cells is not affected, but the sensitivity of the cells to sorafenib can be reduced. The SCRN1-/-tumor cell is more sensitive to sorafenib treatment, and a patient with high SCRN1 expression is more difficult to benefit from sorafenib treatment, so that the invention discloses a new application of the SCRN1 molecule in hepatocellular carcinoma treatment typing and treatment scheme selection, and a new thought and a new way are pro |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN116350785A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN116350785A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN116350785A3</originalsourceid><addsrcrecordid>eNqNyrEKwjAQxvEsDqK-w_kAgqFUXUtQnDqoezjjpT1IkyON728GcXb6Pvj_lsp2IoEdFk4Rkoe7ufUaOI785JJyfSCZBPNPTPRix5HA11wy1RAHGKspyVEI74AZHOZq0oRrtfAYZtp8d6W2l_PDXHckydIs6ChSsabX-tC0--Op7Zp_zAdQRDzc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma</title><source>esp@cenet</source><creator>YU YIZHI ; LI CHUNZHEN ; YIN SHULEI ; XUE YIQUAN ; SHEN XIN ; TAO YIJIE ; XU SHENG ; WU YUNYANG</creator><creatorcontrib>YU YIZHI ; LI CHUNZHEN ; YIN SHULEI ; XUE YIQUAN ; SHEN XIN ; TAO YIJIE ; XU SHENG ; WU YUNYANG</creatorcontrib><description>The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant vector and a hepatocellular carcinoma treatment pharmaceutical composition taking the SCRN1 inhibitor or a recombinant expression vector thereof as an active component. Experimental results show that the expression of SCRN1 in tumor tissues is increased, normal proliferation of liver cancer cells is not affected, but the sensitivity of the cells to sorafenib can be reduced. The SCRN1-/-tumor cell is more sensitive to sorafenib treatment, and a patient with high SCRN1 expression is more difficult to benefit from sorafenib treatment, so that the invention discloses a new application of the SCRN1 molecule in hepatocellular carcinoma treatment typing and treatment scheme selection, and a new thought and a new way are pro</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230630&DB=EPODOC&CC=CN&NR=116350785A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230630&DB=EPODOC&CC=CN&NR=116350785A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YU YIZHI</creatorcontrib><creatorcontrib>LI CHUNZHEN</creatorcontrib><creatorcontrib>YIN SHULEI</creatorcontrib><creatorcontrib>XUE YIQUAN</creatorcontrib><creatorcontrib>SHEN XIN</creatorcontrib><creatorcontrib>TAO YIJIE</creatorcontrib><creatorcontrib>XU SHENG</creatorcontrib><creatorcontrib>WU YUNYANG</creatorcontrib><title>Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma</title><description>The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant vector and a hepatocellular carcinoma treatment pharmaceutical composition taking the SCRN1 inhibitor or a recombinant expression vector thereof as an active component. Experimental results show that the expression of SCRN1 in tumor tissues is increased, normal proliferation of liver cancer cells is not affected, but the sensitivity of the cells to sorafenib can be reduced. The SCRN1-/-tumor cell is more sensitive to sorafenib treatment, and a patient with high SCRN1 expression is more difficult to benefit from sorafenib treatment, so that the invention discloses a new application of the SCRN1 molecule in hepatocellular carcinoma treatment typing and treatment scheme selection, and a new thought and a new way are pro</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQxvEsDqK-w_kAgqFUXUtQnDqoezjjpT1IkyON728GcXb6Pvj_lsp2IoEdFk4Rkoe7ufUaOI785JJyfSCZBPNPTPRix5HA11wy1RAHGKspyVEI74AZHOZq0oRrtfAYZtp8d6W2l_PDXHckydIs6ChSsabX-tC0--Op7Zp_zAdQRDzc</recordid><startdate>20230630</startdate><enddate>20230630</enddate><creator>YU YIZHI</creator><creator>LI CHUNZHEN</creator><creator>YIN SHULEI</creator><creator>XUE YIQUAN</creator><creator>SHEN XIN</creator><creator>TAO YIJIE</creator><creator>XU SHENG</creator><creator>WU YUNYANG</creator><scope>EVB</scope></search><sort><creationdate>20230630</creationdate><title>Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma</title><author>YU YIZHI ; LI CHUNZHEN ; YIN SHULEI ; XUE YIQUAN ; SHEN XIN ; TAO YIJIE ; XU SHENG ; WU YUNYANG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN116350785A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>YU YIZHI</creatorcontrib><creatorcontrib>LI CHUNZHEN</creatorcontrib><creatorcontrib>YIN SHULEI</creatorcontrib><creatorcontrib>XUE YIQUAN</creatorcontrib><creatorcontrib>SHEN XIN</creatorcontrib><creatorcontrib>TAO YIJIE</creatorcontrib><creatorcontrib>XU SHENG</creatorcontrib><creatorcontrib>WU YUNYANG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YU YIZHI</au><au>LI CHUNZHEN</au><au>YIN SHULEI</au><au>XUE YIQUAN</au><au>SHEN XIN</au><au>TAO YIJIE</au><au>XU SHENG</au><au>WU YUNYANG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma</title><date>2023-06-30</date><risdate>2023</risdate><abstract>The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant vector and a hepatocellular carcinoma treatment pharmaceutical composition taking the SCRN1 inhibitor or a recombinant expression vector thereof as an active component. Experimental results show that the expression of SCRN1 in tumor tissues is increased, normal proliferation of liver cancer cells is not affected, but the sensitivity of the cells to sorafenib can be reduced. The SCRN1-/-tumor cell is more sensitive to sorafenib treatment, and a patient with high SCRN1 expression is more difficult to benefit from sorafenib treatment, so that the invention discloses a new application of the SCRN1 molecule in hepatocellular carcinoma treatment typing and treatment scheme selection, and a new thought and a new way are pro</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN116350785A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T18%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YU%20YIZHI&rft.date=2023-06-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN116350785A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |